Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in FSHD1
NCT06222827Phase 2Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Jan 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of satralizumab in facioscapulohumeral muscular dystrophy type 1 (FSHD1), sponsored by Centre Hospitalier Universitaire de Nice. Started Jan 2024; status: active, not recruiting.
02
Drugs
satralizumab
03
Conditions
facioscapulohumeral muscular dystrophy type 1 (FSHD1)
Beyond the preview
Go deeper on NCT06222827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222827.